相似文献
1
COVID-19 in the Immunocompromised Host, Including People with Human Immunodeficiency Virus.免疫功能低下宿主中的 COVID-19，包括人类免疫缺陷病毒感染者。
Infect Dis Clin North Am. 2022 Jun;36(2):397-421. doi: 10.1016/j.idc.2022.01.006. Epub 2022 Feb 1.
2
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies.免疫功能低下人群中的 COVID-19：对预后的影响和免疫疗法的重新应用。
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2021-002630.
3
Coronavirus Disease-2019 in the Immunocompromised Host.新型冠状病毒病在免疫功能低下宿主中的研究进展
Clin Chest Med. 2023 Jun;44(2):395-406. doi: 10.1016/j.ccm.2022.11.012. Epub 2022 Nov 22.
4
Coronavirus Disease-2019 in the Immunocompromised Host.免疫功能低下宿主中的2019冠状病毒病
Infect Dis Clin North Am. 2024 Mar;38(1):213-228. doi: 10.1016/j.idc.2023.12.007.
5
High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge.高滴度疫苗接种后 COVID-19 恢复期血浆用于奥密克戎变异株第一波流行期间免疫功能低下的患者。
Transpl Infect Dis. 2023 Apr;25(2):e14055. doi: 10.1111/tid.14055. Epub 2023 Mar 16.
6
Successful second outpatient autologous hematopoietic cell transplant for relapsed POEMS syndrome in a patient with coexisting HIV, HBV and syphilis infections during the COVID-19 pandemic.在 COVID-19 大流行期间，一名同时合并 HIV、HBV 和梅毒感染的患者，成功进行了复发性 POEMS 综合征的第二次门诊自体造血细胞移植。
Transpl Immunol. 2021 Aug;67:101412. doi: 10.1016/j.trim.2021.101412. Epub 2021 May 19.
7
Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.替沙格韦单抗和西加韦单抗（Evusheld）用于 1112 例严重免疫功能低下患者的 COVID-19 暴露前预防。
Clin Microbiol Infect. 2022 Dec;28(12):1654.e1-1654.e4. doi: 10.1016/j.cmi.2022.07.015. Epub 2022 Aug 1.
8
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.新冠病毒疫苗在免疫功能低下人群中的免疫和临床疗效：一项系统评价
Clin Microbiol Infect. 2022 Feb;28(2):163-177. doi: 10.1016/j.cmi.2021.09.036. Epub 2021 Nov 17.
9
SARS-CoV-2 humoral immunity in people living with HIV-1.SARS-CoV-2 体液免疫与人类免疫缺陷病毒 1 共存者。
Trends Immunol. 2024 Jul;45(7):511-522. doi: 10.1016/j.it.2024.05.005. Epub 2024 Jun 17.
10
Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗接种的有效性及免疫功能低下个体采用替代预防方法的必要性：系统评价的叙述性综述
Expert Rev Vaccines. 2023 Jan-Dec;22(1):341-365. doi: 10.1080/14760584.2023.2191716.
引用本文的文献
1
Impact of oral early antiviral therapies for mild-moderate COVID-19 in the outpatient's setting during Omicron era: a pharmacoeconomic analysis.奥密克戎时代门诊环境中口服早期抗病毒疗法对轻中度新冠肺炎的影响：药物经济学分析
Eur J Med Res. 2024 Dec 19;29(1):597. doi: 10.1186/s40001-024-02154-2.
2
Immunogenicity and Determinants of Antibody Response to the BNT162b2 mRNA Vaccine: A Longitudinal Study in a Cohort of People Living with HIV.BNT162b2 mRNA疫苗的免疫原性及抗体反应的决定因素：一项针对HIV感染者队列的纵向研究
Vaccines (Basel). 2024 Oct 16;12(10):1172. doi: 10.3390/vaccines12101172.
3
Clinical and Imaging Characteristics of SARS-CoV-2 Breakthrough Infection in Hospitalized Immunocompromised Patients.免疫抑制住院患者中 SARS-CoV-2 突破感染的临床和影像学特征。
Korean J Radiol. 2024 May;25(5):481-492. doi: 10.3348/kjr.2023.0992. Epub 2024 Mar 20.
4
Analysis of influencing factors on long COVID in COVID-19 patients infected with omicron variant three months after discharge: a cross-sectional study.奥密克戎变异株感染 COVID-19 患者出院后 3 个月长新冠影响因素分析：一项横断面研究。
BMC Infect Dis. 2024 Jan 2;24(1):36. doi: 10.1186/s12879-023-08947-w.
5
A systematic review and meta-analysis of the global prevalence and determinants of COVID-19 vaccine acceptance and uptake in people living with HIV.对感染艾滋病毒者中新冠病毒疫苗接受度和接种率的全球流行情况及决定因素的系统评价和荟萃分析。
Nat Hum Behav. 2024 Jan;8(1):100-114. doi: 10.1038/s41562-023-01733-3. Epub 2023 Oct 30.
6
COVID-19 in immunocompromised children: comparison of SARS-CoV-2 viral load dynamics between the first and third waves.免疫功能低下儿童中的 COVID-19：第一波和第三波之间 SARS-CoV-2 病毒载量动态的比较。
Braz J Microbiol. 2023 Sep;54(3):1859-1864. doi: 10.1007/s42770-023-01009-y. Epub 2023 Jun 1.
7
Post-COVID Syndrome in Adults-An Overview.成人新冠后遗症概述。
Viruses. 2023 Mar 4;15(3):675. doi: 10.3390/v15030675.
8
COVID-19 vaccine hesitancy among people living with HIV in a low-resource setting: A multi-center study of prevalence, correlates and reasons.在资源匮乏环境下，HIV 感染者对 COVID-19 疫苗的犹豫：一项多中心研究的流行率、相关性和原因。
Vaccine. 2023 Apr 6;41(15):2476-2484. doi: 10.1016/j.vaccine.2023.02.056. Epub 2023 Feb 23.
本文引用的文献
1
Racial and ethnic disparities in coronavirus disease 2019 disease incidence independent of comorbidities, among people with HIV in the United States.美国 HIV 感染者中，2019 年冠状病毒病发病率的种族和民族差异独立于合并症。
AIDS. 2022 Jul 1;36(8):1095-1103. doi: 10.1097/QAD.0000000000003223. Epub 2022 May 6.
2
Factors Associated With Severity of COVID-19 Disease in a Multicenter Cohort of People With HIV in the United States, March-December 2020.2020 年 3 月至 12 月，美国多中心 HIV 感染者队列中 COVID-19 疾病严重程度的相关因素。
J Acquir Immune Defic Syndr. 2022 Aug 1;90(4):369-376. doi: 10.1097/QAI.0000000000002989.
3
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.卡司瑞韦单抗和伊德韦单抗联合治疗住院 COVID-19 患者（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2022 Feb 12;399(10325):665-676. doi: 10.1016/S0140-6736(22)00163-5.
4
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.两种中和单克隆抗体疗法（索特罗维单抗和 BRII-196 加 BRII-198）治疗 COVID-19 住院成人的疗效和安全性（TICO）：一项随机对照试验。
Lancet Infect Dis. 2022 May;22(5):622-635. doi: 10.1016/S1473-3099(21)00751-9. Epub 2021 Dec 23.
5
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.莫努匹韦片用于非住院 COVID-19 患者的口服治疗。
N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.
6
Access to HIV Antiretroviral Therapy among People Living with HIV in Melbourne during the COVID-19 Pandemic.在 COVID-19 大流行期间，墨尔本艾滋病毒感染者获得抗逆转录病毒治疗的情况。
Int J Environ Res Public Health. 2021 Dec 3;18(23):12765. doi: 10.3390/ijerph182312765.
7
SARS-CoV-2 incidence, testing rates, and severe COVID-19 outcomes among people with and without HIV.SARS-CoV-2 感染率、检测率以及 HIV 感染者和非感染者中严重 COVID-19 结局。
AIDS. 2021 Dec 1;35(15):2545-2547. doi: 10.1097/QAD.0000000000003075.
8
Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study.基于人类免疫缺陷病毒（HIV）状态和疫苗类型的新冠病毒（SARS-CoV-2）mRNA疫苗接种后免疫球蛋白G（IgG）浓度及替代病毒中和试验反应的差异：一项配对病例对照观察性研究
Clin Infect Dis. 2022 Aug 24;75(1):e916-e919. doi: 10.1093/cid/ciab1009.
9
COVID-19 Vaccination Rates in a Global HIV Cohort.全球 HIV 队列中的 COVID-19 疫苗接种率。
J Infect Dis. 2022 Feb 15;225(4):603-607. doi: 10.1093/infdis/jiab575.
10
Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status.COVID-19 急性感染严重程度、人口统计学和健康状况与新冠后急性后遗症负担的关系。
Nat Commun. 2021 Nov 12;12(1):6571. doi: 10.1038/s41467-021-26513-3.
Zotero 插件